CTOs on the Move

FatTail

www.fattail.com

 
FatTail is redefining the business of advertising by designing, developing and deploying powerful sales, operations, and marketplace solutions that put you, the publisher, in charge. At the heart of our business is a highly flexible advertising management platform that helps you increase monetization, control, and scale. And instead of asking you to change your business practices to conform to our standards, our software products are readily adaptable to yours, to help you do what you`re already doing – only faster, more efficiently, and more profitably. At FatTail, we are passionate about finding elegant solutions to complex business challenges, particularly those ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.fattail.com
  • 23586 Calabasas Road
    Calabasas, CA USA 91364
  • Phone: 818.615.0380

Executives

Name Title Contact Details

Similar Companies

Questys Solutions

Questys Solutions is a Irvine, CA-based company in the Software and Internet sector.

Apty

Aptys digital adoption platform enables enterprise software adoption at scale. Make any web-based application easier to use through on-screen guidance and data-driven insights.

Satori Software

Satori Software is a Seattle, WA-based company in the Software and Internet sector.

Hover

Find the perfect domain name for your idea at Hover. All domains come with industry-leading customer support and free WHOIS privacy. Name your passion today!

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.